Get the Stockscreener App
22.35
0.72%
0.16
After Hours:
22.35
Acadia Pharmaceuticals Inc stock is traded at $22.35, with a volume of 1.03M.
It is up +0.72% in the last 24 hours and up +0.68% over the past month.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.
See More
Previous Close:
$22.19
Open:
$22.38
24h Volume:
1.03M
Relative Volume:
0.58
Market Cap:
$3.83B
Revenue:
$1.07B
Net Income/Loss:
$391.00M
P/E Ratio:
9.7666
EPS:
2.2884
Net Cash Flow:
$6.31M
1W Performance:
-1.41%
1M Performance:
+0.68%
6M Performance:
+0.09%
1Y Performance:
+47.62%
1-Day Range:
$22.12
$22.70
1-Week Range:
$21.63
$22.73
52-Week Range:
$14.45
$28.35
Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile
Name
Acadia Pharmaceuticals Inc
Sector
Industry
Phone
858-558-2871
Address
12830 EL CAMINO REAL, SAN DIEGO
Compare ACAD vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACAD
Acadia Pharmaceuticals Inc
|
22.35 | 3.80B | 1.07B | 391.00M | 6.31M | 2.2884 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-25-26 | Upgrade | BofA Securities | Neutral → Buy |
| Feb-24-26 | Initiated | Wolfe Research | Outperform |
| Feb-23-26 | Upgrade | Mizuho | Neutral → Outperform |
| Oct-21-25 | Initiated | Citigroup | Buy |
| May-21-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-11-25 | Initiated | Deutsche Bank | Hold |
| Jan-03-25 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Aug-07-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-27-24 | Initiated | BMO Capital Markets | Outperform |
| Mar-12-24 | Downgrade | Mizuho | Buy → Neutral |
| Mar-12-24 | Reiterated | Needham | Buy |
| Jan-30-24 | Initiated | Robert W. Baird | Outperform |
| Jan-24-24 | Upgrade | Needham | Hold → Buy |
| Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-14-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Dec-13-23 | Initiated | Citigroup | Buy |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Nov-06-23 | Upgrade | Mizuho | Neutral → Buy |
| Oct-17-23 | Initiated | UBS | Buy |
| Oct-10-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-03-23 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-04-22 | Downgrade | Goldman | Neutral → Sell |
| Nov-01-22 | Initiated | Loop Capital | Hold |
| Aug-08-22 | Downgrade | Citigroup | Buy → Neutral |
| Aug-05-22 | Downgrade | Citigroup | Buy → Neutral |
| Jun-21-22 | Downgrade | Jefferies | Buy → Underperform |
| Jun-16-22 | Upgrade | Jefferies | Hold → Buy |
| Mar-16-22 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-09-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jan-05-22 | Upgrade | Citigroup | Neutral → Buy |
| Dec-21-21 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-01-21 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-14-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-23-21 | Resumed | Needham | Hold |
| Jun-10-21 | Initiated | Berenberg | Hold |
| Apr-07-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-06-21 | Downgrade | Canaccord Genuity | Buy → Hold |
| Apr-06-21 | Downgrade | Goldman | Buy → Neutral |
| Apr-06-21 | Downgrade | Jefferies | Buy → Hold |
| Apr-06-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-05-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Mar-10-21 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-09-21 | Downgrade | Citigroup | Buy → Neutral |
| Mar-09-21 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-09-21 | Reiterated | H.C. Wainwright | Buy |
| Mar-09-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| Mar-09-21 | Downgrade | Stifel | Buy → Hold |
| Dec-16-20 | Initiated | Mizuho | Buy |
| Nov-16-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Aug-20-20 | Initiated | Morgan Stanley | Overweight |
| Jul-07-20 | Upgrade | Stifel | Hold → Buy |
| Apr-16-20 | Initiated | Jefferies | Buy |
| Mar-31-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-06-20 | Initiated | Citigroup | Buy |
| Dec-16-19 | Initiated | Guggenheim | Buy |
| Oct-24-19 | Initiated | Oppenheimer | Perform |
| Oct-01-19 | Initiated | RBC Capital Mkts | Outperform |
| Sep-13-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-10-19 | Upgrade | Canaccord Genuity | Hold → Buy |
| Jul-23-19 | Reiterated | Needham | Buy |
| Dec-10-18 | Initiated | Canaccord Genuity | Hold |
| Sep-21-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Aug-09-18 | Reiterated | Stifel | Hold |
| Aug-07-18 | Initiated | Stifel | Hold |
| Aug-06-18 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Oct-06-17 | Resumed | Goldman | Neutral |
View All
Acadia Pharmaceuticals Inc Stock (ACAD) Latest News
Acadia Pharmaceuticals officer Kihara sells $29,024 stock - Investing.com
Acadia Pharmaceuticals CFO Mark Schneyer sells $76,395 in stock - Investing.com
ACADIA PHARMACEUTICALS (NASDAQ: ACAD) officer sells shares for RSU tax withholding - Stock Titan
Acadia Pharmaceuticals (ACAD) CFO sells shares to cover RSU taxes - Stock Titan
FDA Approval for NUPLAZID issued to ACADIA PHARMS INC - Quantisnow
MSN Money - MSN
ACADIA Pharmaceuticals (ACAD) Q1 2026 Preview: EPS Est. $0.08, Reports May 6 - AlphaStreet
Acadia Pharmaceuticals appoints Jonathan M. Poole to board of directors - Investing.com
Acadia R&D Chief Plans Retirement As Company Stresses Pipeline Continuity - Sahm
BofA Securities Upgrades ACADIA Pharmaceuticals to Buy Rating - HarianBasis.co
ACADIA (ACAD) Upgraded to Buy After Recent Pullback - Insider Monkey
ACADIA Pharmaceuticals | 8-K: Current report - Moomoo
Acadia Pharmaceuticals Announces Retirement of Head of Research & Development, Ensures Continuity for Alzheimer’s and Lewy Body Dementia Clinical Trials - Minichart
Acadia Announces Planned Retirement of Head of R&D - TipRanks
Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings and Revenue Estimates (Revised) - MSN
Acadia Pharmaceuticals Announces Planned Year-End Retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, Following a Distinguished Career - BioSpace
Acadia Pharmaceuticals (NASDAQ: ACAD) details R&D head’s planned retirement and transition - Stock Titan
Pictet Asset Management Holding SA Buys 84,055 Shares of ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
ACADIA Pharmaceuticals (ACAD) to Release Earnings on Wednesday - MarketBeat
Acadia Pharmaceuticals to Participate at Upcoming May 2026 Investor Conferences - BioSpace
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences - Yahoo Finance
ACADIA Pharmaceuticals | SCHEDULE 13G: Others - Moomoo
Vanguard files Schedule 13G: ACAD (NASDAQ: ACAD) 8.78M shares, 5.15% - Stock Titan
ACAD Stock Price, Quote & Chart | ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) - ChartMill
Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum - Business Wire
Here's why Acadia Pharmaceuticals (ACAD) is a strong momentum stock - MSN
Here's Why Acadia Pharmaceuticals (ACAD) is a Strong Momentum Stock - MSN
Axecap Investments LLC Has $3.65 Million Stock Holdings in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
ACADIA PHARMACEUTICALS INC ($ACAD) CEO 2025 Pay Revealed - Quiver Quantitative
ACADIA Pharmaceuticals | DEF 14A: Definitive information statements - Moomoo
ACADIA Pharmaceuticals Inc. (ACAD) PT Trimmed Slightly as RBC Flags Seasonal Biotech Headwinds - Insider Monkey
Acadia (NASDAQ: ACAD) plans 2026 virtual meeting, equity incentive share increase - Stock Titan
Acadia (ACAD) Stock: Is It Overpriced in Market | Q4 2025: Better Than ExpectedHot Market Picks - Cổng thông tin điện tử Tỉnh Sơn La
5 Most Undervalued Healthcare Stocks to Buy Now - Insider Monkey
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
(ACAD) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Assessing Acadia Pharmaceuticals (ACAD) Valuation After DAYBUE STIX Rollout And Upcoming Neurology Data Presentations - Sahm
Acadia Pharmaceuticals to Present Data at the 2026 American Academy of Neurology (AAN) Annual Meeting - The National Law Review
BofA Securities Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Maintains Target Price $29 - Moomoo
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Short Interest Update - MarketBeat
Acadia Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026 - BioSpace
Acadia Pharmaceuticals to Report Q1 2026 Earnings on May 6 - National Today
How Investors Are Reacting To ACADIA Pharmaceuticals (ACAD) Expanding DAYBUE STIX Access for Rett Syndrome - Yahoo Finance
Press Release: Acadia Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026 - Moomoo
ACADIA Pharmaceuticals stock (US0042251084): Is the next product pipeline now the real test for sust - AD HOC NEWS
Acadia launches powder version of Rett syndrome treatment in the US - MSN
ACADIA Pharmaceuticals Announces Advancement by Allergan of Novel Glaucoma Compound into Preclinical - Yahoo
A Look At Acadia Pharmaceuticals (ACAD) Valuation After DAYBUE STIX US Launch - Sahm
Acadia Pharmaceuticals Inc Stock (ACAD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):